Vernalis plc (LON:VER) Earns Hold Rating from Panmure Gordon
A number of other equities research analysts also recently commented on the company. Numis Securities Ltd reiterated an add rating and issued a GBX 29 ($0.38) target price on shares of Vernalis plc in a research report on Friday, April 21st. N+1 Singer reiterated a hold rating and issued a GBX 28 ($0.36) target price on shares of Vernalis plc in a research report on Friday, April 21st. Stifel Nicolaus decreased their target price on Vernalis plc from GBX 29 ($0.38) to GBX 24 ($0.31) and set a hold rating on the stock in a research report on Friday, April 21st. Finally, RX Securities reiterated a buy rating on shares of Vernalis plc in a research report on Monday. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of Hold and an average price target of GBX 39.40 ($0.51).
Vernalis plc (VER) opened at 16.25 on Monday. The company’s 50 day moving average price is GBX 18.04 and its 200-day moving average price is GBX 22.16. Vernalis plc has a one year low of GBX 15.98 and a one year high of GBX 46.00. The stock’s market capitalization is GBX 85.53 million.
About Vernalis plc
Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.
Receive News & Stock Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related stocks with our FREE daily email newsletter.